Two-drug vs . three-drug combinations for HIV-1: Do we have enough data to make the switch?
出版年份 2019 全文链接
标题
Two-drug vs
. three-drug combinations for HIV-1: Do we have enough data to make the switch?
作者
关键词
-
出版物
HIV MEDICINE
Volume 20, Issue -, Pages 2-12
出版商
Wiley
发表日期
2019-03-01
DOI
10.1111/hiv.12716
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study
- (2018) Cristina Mussini et al. BMC Medicine
- Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0
- (2018) L Ryom et al. HIV MEDICINE
- Secular trends in opportunistic infections, cancers and mortality in patients with AIDS during the era of modern combination antiretroviral therapy
- (2018) E Sezgin et al. HIV MEDICINE
- Brief Report
- (2018) Jose R. Castillo-Mancilla et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy
- (2018) Simone Belmonti et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART
- (2018) Monica Gandhi et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
- (2018) Josep M Llibre et al. LANCET
- The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial
- (2018) Thomas A Rasmussen et al. Lancet HIV
- Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
- (2018) Pedro Cahn et al. LANCET
- Re-evaluating evolution in the HIV reservoir
- (2017) Daniel I. S. Rosenbloom et al. NATURE
- Impact of monotherapy on HIV-1 reservoir, immune activation, and co-infection with Epstein-Barr virus
- (2017) Maria Raffaella Petrara et al. PLoS One
- Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
- (2017) Pedro Cahn et al. Journal of the International AIDS Society
- Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation
- (2017) Rajesh T. Gandhi et al. PLoS Pathogens
- Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial
- (2017) Ingeborg Wijting et al. Lancet HIV
- The effect of treatment simplification on HIV reservoirs
- (2017) Gilles Darcis et al. Lancet HIV
- Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers
- (2017) Fanny Chereau et al. PLoS One
- Immune tolerance properties of the testicular tissue as a viral sanctuary site in ART-treated HIV-infected adults
- (2016) Mohammad-Ali Jenabian et al. AIDS
- Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia
- (2016) Amélie Guihot et al. AIDS
- Update of Survival for Persons With HIV Infection in Denmark
- (2016) Nicolai Lohse et al. ANNALS OF INTERNAL MEDICINE
- Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study
- (2016) Alessandra Latini et al. BMC INFECTIOUS DISEASES
- Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression
- (2016) Jose R. Castillo-Mancilla et al. CLINICAL INFECTIOUS DISEASES
- The role of tenofovir alafenamide in future HIV management
- (2016) A Antela et al. HIV MEDICINE
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
- (2016) Huldrych F. Günthard et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site
- (2016) Yiying Huang et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Persistent HIV-1 replication maintains the tissue reservoir during therapy
- (2016) Ramon Lorenzo-Redondo et al. NATURE
- Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis
- (2016) Narendran Gopalan et al. AIDS Research and Therapy
- Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients
- (2016) Jean-Guy Baril et al. PLoS One
- Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy
- (2015) M Younas et al. HIV MEDICINE
- Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
- (2015) José R Arribas et al. LANCET INFECTIOUS DISEASES
- Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
- (2015) José A Perez-Molina et al. LANCET INFECTIOUS DISEASES
- Differential Effects of Viremia and Microbial Translocation on Immune Activation in HIV-Infected Patients Throughout Ritonavir-Boosted Darunavir Monotherapy
- (2015) Omar J. BenMarzouk-Hidalgo et al. MEDICINE
- Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non–AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment
- (2014) Allan R. Tenorio et al. JOURNAL OF INFECTIOUS DISEASES
- Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial
- (2014) François Raffi et al. LANCET
- Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial
- (2014) Pedro Cahn et al. LANCET INFECTIOUS DISEASES
- The Impact of Antiretroviral Therapy on Mortality in HIV Positive People during Tuberculosis Treatment: A Systematic Review and Meta-Analysis
- (2014) Anna Odone et al. PLoS One
- The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL
- (2014) Andrea Antinori et al. Journal of the International AIDS Society
- Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation
- (2014) Berta Torres et al. Journal of the International AIDS Society
- HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality
- (2014) Sergio Serrano-Villar et al. PLoS Pathogens
- HIV infection of human regulatory T cells downregulates Foxp3 expression by increasing DNMT3b levels and DNA methylation in the FOXP3 gene
- (2013) Marjorie Pion et al. AIDS
- Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study
- (2013) R Weber et al. HIV MEDICINE
- Long-Term Suppressive Combined Antiretroviral Treatment Does Not Normalize the Serum Level of Soluble CD14
- (2013) G. Mendez-Lagares et al. JOURNAL OF INFECTIOUS DISEASES
- Increase in 2–Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial
- (2013) Hiroyu Hatano et al. JOURNAL OF INFECTIOUS DISEASES
- Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen
- (2013) Clotilde Allavena et al. JOURNAL OF MEDICAL VIROLOGY
- Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers
- (2013) Hiroyu Hatano et al. PLoS Pathogens
- Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients
- (2012) Jean-Philippe Bastard et al. ANTIVIRAL THERAPY
- HIV-1 Antiretroviral Resistance
- (2012) Michele W. Tang et al. DRUGS
- Low-Level HIV Viremia Is Associated With Microbial Translocation and Inflammation
- (2012) Sergio Reus et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- The Expression of Cholesterol Metabolism Genes in Monocytes From HIV-Infected Subjects Suggests Intracellular Cholesterol Accumulation
- (2012) Eoin R. Feeney et al. JOURNAL OF INFECTIOUS DISEASES
- Cell-Based Measures of Viral Persistence Are Associated With Immune Activation and Programmed Cell Death Protein 1 (PD-1)–Expressing CD4+ T cells
- (2012) Hiroyu Hatano et al. JOURNAL OF INFECTIOUS DISEASES
- HIV Infection, Immune Suppression, and Uncontrolled Viremia Are Associated With Increased Multimorbidity Among Aging Injection Drug Users
- (2011) M. L. Salter et al. CLINICAL INFECTIOUS DISEASES
- Relationship Between Residual Plasma Viremia and the Size of HIV Proviral DNA Reservoirs in Infected Individuals Receiving Effective Antiretroviral Therapy
- (2011) Tae-Wook Chun et al. JOURNAL OF INFECTIOUS DISEASES
- Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy
- (2010) Steven A Yukl et al. AIDS
- Causes of Death in HIV‐1–Infected Patients Treated with Antiretroviral Therapy, 1996–2006: Collaborative Analysis of 13 HIV Cohort Studies
- (2010) CLINICAL INFECTIOUS DISEASES
- Differences in HIV Burden and Immune Activation within the Gut of HIV‐Positive Patients Receiving Suppressive Antiretroviral Therapy
- (2010) Steven A. Yukl et al. JOURNAL OF INFECTIOUS DISEASES
- HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
- (2010) Maria J Buzón et al. NATURE MEDICINE
- The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
- (2010) Rajesh T. Gandhi et al. PLOS MEDICINE
- Inferior Clinical Outcome of the CD4+Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+Cell Counts and HIV RNA Levels during Follow‐up
- (2008) JOURNAL OF INFECTIOUS DISEASES
- Human Immunodeficiency Virus (HIV)-1 Viral Protein R Suppresses Transcriptional Activity of Peroxisome Proliferator-Activated Receptor γ and Inhibits Adipocyte Differentiation: Implications for HIV-Associated Lipodystrophy
- (2007) Shashi Shrivastav et al. MOLECULAR ENDOCRINOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now